Ironwood Pharmaceuticals, Inc. (IRWD) CFO Gina Consylman Sells 4,055 Shares

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Gina Consylman sold 4,055 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $10.53, for a total value of $42,699.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Gina Consylman also recently made the following trade(s):

  • On Thursday, February 21st, Gina Consylman sold 5,677 shares of Ironwood Pharmaceuticals stock. The shares were sold at an average price of $14.31, for a total value of $81,237.87.

Shares of NASDAQ:IRWD traded up $0.24 during midday trading on Thursday, hitting $10.04. The company’s stock had a trading volume of 14,388 shares, compared to its average volume of 1,498,202. The company has a market cap of $1.52 billion, a P/E ratio of -10.43 and a beta of 1.89. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $9.07 and a fifty-two week high of $21.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.10). The company had revenue of $68.73 million during the quarter, compared to analyst estimates of $81.93 million. During the same quarter in the previous year, the business posted ($0.25) earnings per share. The firm’s quarterly revenue was down .6% compared to the same quarter last year. Research analysts predict that Ironwood Pharmaceuticals, Inc. will post -0.12 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. CWM LLC acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $31,000. CWM Advisors LLC acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth about $154,000. First Manhattan Co. acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $133,000. Gotham Asset Management LLC acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $135,000. Finally, NumerixS Investment Technologies Inc acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth about $190,000. 97.04% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently issued reports on IRWD shares. BidaskClub upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. HC Wainwright upgraded Ironwood Pharmaceuticals from a “sell” rating to a “neutral” rating and increased their target price for the company from $11.50 to $14.00 in a report on Monday, February 25th. Morgan Stanley set a $13.00 target price on Ironwood Pharmaceuticals and gave the company a “hold” rating in a report on Friday, May 3rd. Wood & Company reiterated a “buy” rating on shares of Ironwood Pharmaceuticals in a report on Thursday, January 31st. Finally, Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, January 28th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the stock. Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average target price of $15.15.

WARNING: This news story was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thestockobserver.com/2019/05/16/ironwood-pharmaceuticals-inc-irwd-cfo-gina-consylman-sells-4055-shares.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Recommended Story: Why is the Consumer Price Index (CPI) important?

Insider Buying and Selling by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.